share_log

Barclays Maintains Underweight on Chimera Investment, Lowers Price Target to $9

Benzinga Real-time News ·  Jul 18, 2022 07:08

Barclays analyst Mark Devries maintains Chimera Investment (NYSE:CIM) with a Underweight and lowers the price target from $11 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment